Galapagos reported mixed topline readouts for its selective TYK2 inhibitor GLPG3667: a Phase 3–enabling dermatomyositis study met its primary endpoint at 24 weeks, while a parallel Phase 3–enabling systemic lupus erythematosus trial did not meet the primary endpoint at week 32. In the dermatomyositis study, once-daily 150 mg GLPG3667 added to standard of care achieved a statistically significant improvement on the Total Improvement Score under a pre-specified 10% significance level, alongside meaningful gains on several secondary measures of disease activity and a favorable safety profile. The SLE study, testing 75 mg and 150 mg doses on top of standard therapy, showed numerical improvements on multiple secondary endpoints—particularly in skin—but missed the primary dose-response endpoint on SRI-4. The SLE trial continues to 48 weeks with final data expected in the second quarter of 2026. Galapagos will evaluate strategic options, including resuming partnering for dermatomyositis and potentially expanding into other severe autoimmune indications. Gilead has temporarily waived certain rights under its collaboration to enable external partnership discussions on GLPG3667.
The core question is whether an ATP-competitive TYK2 approach can carve out a defensible niche as the class evolves beyond psoriasis. With allosteric TYK2 agents already on market in common derm conditions and multiple late-stage competitors in play, differentiation will likely hinge on disease selection, safety, and functional outcomes that translate into payer acceptance. Dermatomyositis offers a compelling route: a rare, high-morbidity autoimmune disease with only one approved therapy and clear unmet need across muscle and skin domains. However, the signal so far is based on a small dataset and a lenient alpha, which raises the bar for a pivotal program to produce durable, clinically meaningful effects under conventional statistical thresholds.
For patients and HCPs, the appeal of a once-daily oral option that spans muscle and cutaneous disease activity is obvious, provided the safety profile remains clean and steroid-sparing potential is demonstrated. Payers will look for consistency across endpoints, reductions in exacerbations and healthcare utilization, and quality-of-life gains captured with validated instruments used by myositis centers. The cutaneous signals emerging in SLE could point to opportunities in cutaneous lupus or dermatomyositis subphenotypes where skin burden drives disability and costs, but the heterogeneous, flare-prone nature of SLE continues to frustrate development and dilutes class read-through.
Commercially, the partnering pivot matters. Capital-efficient development in a rare rheumatologic indication can compress timelines and de-risk balance sheets, while allowing a partner with rheum-derm commercial infrastructure to build the market across specialized centers. Gilead’s flexibility underscores a broader shift in collaboration models, as larger pharmas selectively loosen option rights to catalyze external capital and accelerate de-risking in programs that sit adjacent to their core priorities. Across immunology, the TYK2 field is bifurcating: scaled assets chasing broad endemic indications, and targeted plays moving into orphan, mechanism-rich spaces where RWE, KOL networks, and focused market access work can unlock premium pricing.
The next inflection will be design choices for a registrational dermatomyositis program: endpoint hierarchy, muscle and skin domain weighting, background therapy control, and a path to demonstrate sustained benefit beyond 24 weeks. If Galapagos can secure a capable partner before the full SLE readout, it can lean into dermatomyositis momentum and hedge against lupus uncertainty. The strategic test for the class is now clear: can kinase-domain TYK2 inhibition deliver a label with a differentiated safety and efficacy story in rare autoimmune disease—and will payers reward that differentiation with rapid access and durable coverage?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
